{
    "zip": "60064",
    "sector": "Healthcare",
    "fullTimeEmployees": 30000,
    "longBusinessSummary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Beh\u00e7et's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstr\u00f6m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.",
    "city": "North Chicago",
    "phone": "847 932 7900",
    "state": "IL",
    "country": "United States",
    "companyOfficers": [],
    "website": "http://www.abbvie.com",
    "maxAge": 1,
    "address1": "1 North Waukegan Road",
    "industry": "Drug Manufacturers\u2014General",
    "previousClose": 87.57,
    "regularMarketOpen": 89.27,
    "twoHundredDayAverage": 81.77713,
    "trailingAnnualDividendYield": 0.05013132,
    "payoutRatio": 0.8106,
    "volume24Hr": null,
    "regularMarketDayHigh": 91.86,
    "navPrice": null,
    "averageDailyVolume10Day": 12761542,
    "totalAssets": null,
    "regularMarketPreviousClose": 87.57,
    "fiftyDayAverage": 88.77294,
    "trailingAnnualDividendRate": 4.39,
    "open": 89.27,
    "averageVolume10days": 12761542,
    "expireDate": null,
    "yield": null,
    "algorithm": null,
    "dividendRate": 4.72,
    "exDividendDate": 1586822400,
    "beta": 0.965547,
    "circulatingSupply": null,
    "startDate": null,
    "regularMarketDayLow": 88.95,
    "priceHint": 2,
    "currency": "USD",
    "trailingPE": 17.376894,
    "regularMarketVolume": 16328804,
    "lastMarket": null,
    "maxSupply": null,
    "openInterest": null,
    "marketCap": 135712931840,
    "volumeAllCurrencies": null,
    "strikePrice": null,
    "averageVolume": 8960540,
    "priceToSalesTrailing12Months": 4.079629,
    "dayLow": 88.95,
    "ask": 0,
    "ytdReturn": null,
    "askSize": 800,
    "volume": 16328804,
    "fiftyTwoWeekHigh": 97.86,
    "forwardPE": 8.721482,
    "fromCurrency": null,
    "fiveYearAvgDividendYield": 3.8,
    "fiftyTwoWeekLow": 62.66,
    "bid": 91.43,
    "tradeable": true,
    "dividendYield": 0.0539,
    "bidSize": 1200,
    "dayHigh": 91.86,
    "exchange": "NYQ",
    "shortName": "AbbVie Inc.",
    "longName": "AbbVie Inc.",
    "exchangeTimezoneName": "America/New_York",
    "exchangeTimezoneShortName": "EST",
    "isEsgPopulated": false,
    "gmtOffSetMilliseconds": "-18000000",
    "quoteType": "EQUITY",
    "symbol": "ABBV",
    "messageBoardId": "finmb_141885706",
    "market": "us_market",
    "annualHoldingsTurnover": null,
    "enterpriseToRevenue": 4.71,
    "beta3Year": null,
    "profitMargins": 0.23694,
    "enterpriseToEbitda": 9.972,
    "52WeekChange": 0.12139845,
    "morningStarRiskRating": null,
    "forwardEps": 10.52,
    "revenueQuarterlyGrowth": null,
    "sharesOutstanding": 1478819968,
    "fundInceptionDate": null,
    "annualReportExpenseRatio": null,
    "bookValue": -5.526,
    "sharesShort": 79022759,
    "sharesPercentSharesOut": 0.053400002,
    "fundFamily": null,
    "lastFiscalYearEnd": 1577750400,
    "heldPercentInstitutions": 0.77615,
    "netIncomeToCommon": 7841999872,
    "trailingEps": 5.28,
    "lastDividendValue": null,
    "SandP52WeekChange": 0.08368194,
    "priceToBook": null,
    "heldPercentInsiders": 0.00124,
    "nextFiscalYearEnd": 1640908800,
    "mostRecentQuarter": 1577750400,
    "shortRatio": 7.41,
    "sharesShortPreviousMonthDate": 1579046400,
    "floatShares": 1476642117,
    "enterpriseValue": 156693757952,
    "threeYearAverageReturn": null,
    "lastSplitDate": null,
    "lastSplitFactor": null,
    "legalType": null,
    "morningStarOverallRating": null,
    "earningsQuarterlyGrowth": null,
    "dateShortInterest": 1581638400,
    "pegRatio": 1.86,
    "lastCapGain": null,
    "shortPercentOfFloat": 0.060599998,
    "sharesShortPriorMonth": 76675797,
    "category": null,
    "fiveYearAverageReturn": null,
    "regularMarketPrice": 89.27,
    "logo_url": "https://logo.clearbit.com/abbvie.com"
}